Interestingly, this increase in cancer cell migration could be inhibited by combined treatment with VEGFR2 and EGFR antibodies, as was demonstrated by a decreased migration of glioblastoma cells in an in vitro system (94, 95). This evidence concerns the gene KDR and glioblastoma.